Bristol-Myers Squibb Company
Anti-GITR antibodies for cancer diagnostics

Last updated:

Abstract:

Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy.

Status:
Grant
Type:

Utility

Filling date:

8 May 2020

Issue date:

9 Aug 2022